Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma

OBJECTIVE: The mainstay treatment of esophageal squamous cell carcinoma (ESCC) involves chemotherapy and immunotherapy. However, alternative therapies are required for patients who are refractory or intolerant to existing therapies. METHODS: In this single-arm, multicenter, open-label phase Ib study...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Ming, Wang, Meng, Deng, Ting, Bai, Yuxian, Zang, Kai, Miao, Zhanhui, Gai, Wenlin, Xie, Liangzhi, Ba, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958882/
https://www.ncbi.nlm.nih.gov/pubmed/35014769
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958882/
https://www.ncbi.nlm.nih.gov/pubmed/35014769
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0388

Ejemplares similares